anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will utilize a rigorous multi-method, multi-informant design to examine the effects of dyadic neurofeedback (dnf) on adolescent brain activation with fMRI hyperscanning. Parents and adolescents will also report on emotion regulation, depressive symptoms, and parenting practices. Data collection procedures will take place at the Laureate Institute for Brain Research (LIBR), which is equipped with two identical scanners that have advanced real-time fMRI systems capable of conducting parallel fMRI hyperscanning, including the capacity for neurofeedback. Parents will complete a phone screen to determine initial eligibility. If initial study criteria are met, a 2-hour in-person lab visit will be scheduled where mothers and daughters will complete consent/assent; diagnostic interviews; surveys on emotion regulation, parenting practices, depression, and anxiety; and additional screening. Survey data will be used for preliminary exploratory analyses. Based on data collected from the screening visit, participants will be invited to participate in the full study: a 4-hour visit where mothers and daughters will complete emotion ratings, mock scanner training, and fMRI tasks individually and together using hyperscanning (scan time = 16 min resting-state \[2 runs\], 7 min structural MRI, 40 min fMRI tasks, 10 min clinical MRI scans).
Systems and methods are presented herein for providing a user with a recommendation for physical activity related to media content. The user may activate a recommendation application setting on a user equipment device. The user may select a media asset for presentation on a user equipment device. The system may analyze data associated with the media asset and perform deep video analysis of the frames of the media asset to identify events in the media asset. The system may identify the content type of each respective segment of the media asset and may identify respective activities performed in each segment by a primary character. The system may determine a respective activity to recommend to the user for reach respective segment of the media asset. The application may then determine a segment is being displayed for a user and generate an overlay representing a physical activity for the user to perform.
Based on the unmet medical need for new agents in the treatment of asthma and the role of KCa3.1 in the function of several different cell types involved in the inflammatory response, and the effects seen in an animal model of allergic asthma, it is reasonable to explore the utility of senicapoc, a KCa3.1 blocker, as a novel treatment of asthma. This study will test the ability of senicapoc to alleviate bronchospasm induced by an exercise challenge in subjects with asthma. Exercise challenge studies have been conducted for many currently approved asthma medications. Exercise challenge studies provide a controlled environment and test conditions to investigate the potential usefulness of novel study drugs for the treatment of asthma. This study will be the first to test the ability of senicapoc to reduce airway bronchospasm after exercise challenge, which is one clinically important manifestation of asthma seen in patients. In summary, with a demonstrated safety profile across a wide range of doses in humans and efficacy in an animal model of allergic bronchospasm and hyper-responsiveness, the initiation of exploratory studies of senicapoc for treatment of asthma is justified.
PURPOSE: To obtain a glutamic acid derivative usable as a synthetic intermediate for a sugar-modified polyglutamic acid derivative useful as a drug delivery carrier having organotropic property. CONSTITUTION: This glutamic acid derivative is expressed by formula I (R3 is 9-fluorenylmethoxycarbonyl; R4 is a carboxyl-protecting group). The compound is produced by reacting the α-amino group of glutamic acid having protected γ-carboxyl group with a reactive derivative of 9-fluorenylmethoxycarboxylic acid, e.g. by reacting the acid with succinimide, protecting the α-carboxyl group and eliminating the protective group of the γ-carboxyl group. The compound of formula I can be converted to a compound of formula II (R2 is glucosyl; (n) is 7-10) by selecting the 9-fluorenylmethoxycarbonyl for the protection of the amino group of glutamic acid.  Further, the compound of formula II is converted to a sugar-modified polyglutamic acid derivative of formula III (R1 is OR' or NHR"; R' is H, an alkali metal, etc.; R" is H or a physiologically active substance; the molar ratio of (m) to (k) is 1-100).
<P>PROBLEM TO BE SOLVED: To provide an antiviral agent which excels in safety, enables daily medication/intake over a long time, and has an antiviral action against pathogenic virus of the cause of infectious diseases of animals including a human.  <P>SOLUTION: The antiviral agent has a pepsin hydrolyzate of lactoferrin as an active ingredient and particularly exhibits an antiviral action against RS virus. The antiviral agent has a peptide described in Sequence No. 1 as an active ingredient, and particularly exhibits an antiviral action against RS virus or influenza virus. A food and a drink or a feed contains the antiviral agent.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).
This is a pediatric phase I dose escalation study to determine a biologically active dose and to obtain information concerning the safety, tolerability, and pharmacokinetics of capravirine (AG 1549)(5-\[(3,5-dichlorophenyl)thio\]-4-(1-methylethyl)-1-(4-pyridinylmethyl)-1H-imidazol-2-methanol carbamate), a potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitor, that induces a novel pattern of resistance mutations. In addition to obtaining needed biological activity, pediatric safety, tolerability, and pharmacokinetic data, the study will utilize capravirine's potent antiretroviral activity and novel resistance mutation pattern, together with serial measurements of plasma HIV viral load, flow cytometry, and genotypic and phenotypic viral resistance analysis to conduct pilot studies in pediatric HIV pathogenesis, the response to antiretroviral therapy, and to develop strategies to optimize the management of pediatric antiretroviral therapy. We will also use initial viral decay dynamics and other patient characteristics to model predictions for the long-term response to antiretroviral therapy. We will enroll children who have become refractory to or have experienced toxicity on prior therapy. The study will include resistance testing on the failing regimen, a one week period off antiretrovirals (washout period), an initial 6 days of capravirine monotherapy followed by capravirine in combination with the optimal antiretroviral therapy as determined by their baseline viral resistance mutation pattern and history. The patients will be followed for at least 48 weeks to assess long-term tolerability and toxicity, and to assess the clinical, virological, and immunological response to capravirine.
Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
A method of improving vascular function comprising administering to a subject in need thereof grape seed extract. The grape seed extract is added to foodstuff products to form a functional food. The extract of the invention contains 30-90% w/w polyphenols measured as gallic acid equivalent. Polyphenols in grape seed extract may be present as oligomeric and polymeric proanthocyanidins. In a preferred form of the invention 60-90 % w/w of the total polyphenol component present is polymeric in form and more preferably has 2-16 monomeric units in each polymeric molecule. The polyphenols present in the composition of the invention contain less than 1% w/w flavonols.
Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 0/10 on the numerical pain rating scale (NPRS) with 0 being "no pain at all" and 10 being "the worst pain imaginable". The stimulation will be carried out for 2 minutes.
Rationale: Chronic lung allograft dysfunction (CLAD) is the leading cause of death after lung transplant, and azithromycin has variable efficacy in CLAD. The lung microbiome is a risk factor for developing CLAD, but the relationship between lung dysbiosis, pulmonary inflammation, and allograft dysfunction remains poorly understood. Whether lung microbiota predict outcomes or modify treatment response after CLAD is unknown. Objectives: To determine whether lung microbiota predict post-CLAD outcomes and clinical response to azithromycin. Methods: Retrospective cohort study using acellular BAL fluid prospectively collected from recipients of lung transplant within 90 days of CLAD onset. Lung microbiota were characterized using 16S rRNA gene sequencing and droplet digital PCR. In two additional cohorts, causal relationships of dysbiosis and inflammation were evaluated by comparing lung microbiota with CLAD-associated cytokines and measuring ex vivo P. aeruginosa growth in sterilized BAL fluid. Measurements and Main Results: Patients with higher bacterial burden had shorter post-CLAD survival, independent of CLAD phenotype, azithromycin treatment, and relevant covariates. Azithromycin treatment improved survival in patients with high bacterial burden but had negligible impact on patients with low or moderate burden. Lung bacterial burden was positively associated with CLAD-associated cytokines, and ex vivo growth of P. aeruginosa was augmented in BAL fluid from transplant recipients with CLAD. Conclusions: In recipients of lung transplants with chronic rejection, increased lung bacterial burden is an independent risk factor for mortality and predicts clinical response to azithromycin. Lung bacterial dysbiosis is associated with alveolar inflammation and may be promoted by underlying lung allograft dysfunction.
The purpose of our study was to investigate the effect of home-based mobile-guided exercise-based cardiac rehabilitation on the improvement of exercise capacity among patients undergoing transcatheter aortic valve replacement. 90 subjects will be recruited and followed up for a six-minute walk distance, short physical performance battery, exercise adherence, quality of life, frailty, nutritional status, sleep status, readmission rate, and all-cause mortality et al. The subjects will be invited to participate in on-site visits at 1, 3, and 6 months. Patients in the interventional group will receive a home-based mobile-guided exercise-based cardiac rehabilitation for 3 months. The home-based mobile-guided exercise-based cardiac rehabilitation is a multi-component intervention strategy including the preparation for discharge, family support, motivational interviews, health education, telephone follow-up, wearable devices, APP, et al. While the patients in the control group will receive routine care. For example, the preparation for discharge of the control group does not include the guidance of mobile-guided exercise-based cardiac rehabilitation, family support, and motivational interviews. After discharge, nurses will conduct telephone follow-ups once a month for the control group. Baseline data and outcomes will be collected in a Case Report Form.
The present invention discloses a Chinese medical preparation for treating gastric diseases, which is composed of the following raw materials according to the weight portion proportioning: 0.6 to 0.9 (portions) of eaglewood wood, 5 to 15 (portions) of notoginseng, 6 to 12 (portions) of cuttle bone, 2 to 10 (portions) of amomun fruit, 6 to 15 (portions) of bletilla tuber, 5 to 15 (portions) of white atractylodes rhizome and 10 to 30 (portions) of iron ocher. The prescription of the present invention is superior, and seven Chinese herbal medicines are chosen from thousands of Chinese medicines, and are quantitatively mixed. The fabrication process is simple, and six traditional Chinese medicines are directly mixed and ground to powder by a traditional technology. The capsulation and the administration are convenient and safe, and the medicine is completely dissolved in a gastral cavity for fully exerting the drug effect. The cost is low, because most Chinese herbal medicines in the prescription are common, the manufacture cost is low, so the present invention is suitable for underprivileged group people. The effect is good, the product is pure Chinese medicine preparation, and is a secret recipe handed down from generation of the inventor. By combining medical practice of more than 20 years and through the clinic trial of near ten thousands of patients, the cure rate of gastritis reaches 95%, the cure rate of gastroptosis reaches 85%, the cure rate of duodenal ulcer reaches more than 90%, and the cure rate of gastric ulcer reaches 90%.
A system is provided herein for stimulating an anatomical element of a patient. For example, a device may be configured to generate a current, and an electrode device coupled to the device may be configured to apply the current to the anatomical element. Additionally, the system may include a user interface in communication with the implantable pulse generator, the electrode device, or both. In some examples, the user interface may include a first element that is configured to display information associated with the patient. Additionally, the user interface may include a second element that is configured to receive inputs for programming parameters of the current. The user interface may also include a third element that is configured to display diagnostic information associated with applying the current to the anatomical element.
Individuals will receive a kit with medication adherence devices containing the placebo pills in one of three smart electronic pill bottles labeled "A," "B," and "C." Participants will not be aware which of the pill bottles contains the placebo. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive the placebo, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The placebo will be administered in 2 intervention periods each 2 weeks in length (4 weeks total).
BACKGROUND: Loxoscelism is a toxic clinical condition caused by the bite of spiders of the genus Loxosceles, with wide distribution throughout the world.1 Phospholipase D is responsible for dermonecrosis, inflammation, platelet aggregation, hemolysis, alteration of vascular permeability, cytotoxicity, nephrotoxicity, acute renal failure, among other symptoms involved with this protein.
CASE REPORT: 27-year-old male patient, who began with a sudden episode of intense pain in the right hand, in the metacarpus and metacarpophalangeal joints. On clinical examination, the upper extremity was noted to have increased volume, extensive edema, hyperemia, and increased local temperature; The lesion progressed to extensive necrosis. Fasciotomies were performed, from distal to proximal, and release of the second and third finger compartment through longitudinal radial and ulnar incisions. A skin autograft was placed, obtained from the anterior surface of the right thigh. Opioid analgesics, non-steroidal anti-inflammatory drugs, corticosteroids, and antibiotics were administered. The skin biopsy reported: inflammatory infiltrate with neutrophils, ulceration, and bacterial colonies. After 27 days he had a favorable evolution, so he was discharged to his home, with follow-up by staff from the Outpatient Service.
CONCLUSION: Cutaneous loxoscelism, as a cause of acute compartment syndrome of the hand, is rare, but should be considered in an area endemic for Loxosceles spp. Surgical decompression of the affected compartments represents a decisive factor in the treatment of patients.
Pregnancy-related low back pain is experienced by over half of all pregnant women. In the United States it is thought of as a normal constituent of pregnancy. However, in Europe low back pain associated with pregnancy is treated. In the United States pregnancy-related low back pain is thought to resolve with birth. However about 1/3 of women who experience pregnancy-related low back pain continue to experience back pain for one year postpartum. Those women whose low back pain persists into the postpartum period are more at risk of experiencing comorbidities such as postpartum depression.

In the extrauterine life maternal pain limits a mother's ability to securely attach with her child. Furthermore, interpretation of pain intensity is influenced by the type of attachment the individual has with her parents. Little is known how maternal pain may influence intrauterine attachment. Similarly, heart rate variability is influenced by pain and by spinal manipulation in non-pregnant populations. However, normal non-pregnant patterns of heart rate variability are altered during the second and third trimesters of pregnancy, and little is known about why this happens or what this means.
Scarring, a prevalent issue in clinical settings, is characterized by the excessive generation of extracellular matrix within the skin tissue. Among the numerous regulatory factors implicated in fibrosis across various organs, the apelin/APJ axis has emerged as a potential regulator of fibrosis. Given the shared attribute of heightened extracellular matrix production between organ fibrosis and scarring, we hypothesize that the apelin/APJ axis also plays a regulatory role in scar development. In this study, we examined the expression of apelin and APJ in scar tissue, normal skin, and fibroblasts derived from these tissues. We investigated the impact of the hypoxic microenvironment in scars on apelin/APJ expression to identify the transcription factors influencing apelin/APJ expression. Through overexpressing or knocking down apelin/APJ expression, we observed their effects on fibroblast secretion of extracellular matrix proteins. We further validated these effects in animal experiments while exploring the underlying mechanisms. Our findings demonstrated that the apelin/APJ axis is expressed in fibroblasts from keloid, hypertrophic scar, and normal skin. The regulation of apelin/APJ expression by the hypoxic environment in scars plays a significant role in hypertrophic scar and keloid development. This regulation promotes extracellular matrix secretion through upregulation of TGF-β1 expression via the PI3K/Akt/CREB1 pathway.
This is a randomized (study drug assigned by chance), multicenter (when more than one hospital or medical school team work on a medical research study), Phase 3 trial to evaluate the efficacy and safety of trabectedin as compared to standard doxorubicin in participants with advanced TRS. Participants will be randomized in a 1:1 ratio to either of the 2 treatment groups, that is, trabectedin or doxorubicin plus ifosfamide group. Participants in trabectedin group will receive trabectedin 1.5 milligram per square meter (mg/m\^2) given as a 24-hour continuous intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every 3 weeks and in doxorubicin plus ifosfamide group participants will receive doxorubicin 60 or 75 mg/m\^2 intravenously every 3 weeks followed by ifosfamide 6 to 9 gram (g)/m\^2 every 3 weeks. Participants in either treatment arm will continue receiving therapy in the absence of progressive disease (PD) or intolerable side effects, until the participants' consent is withdrawn or the eligibility criteria for continuing treatment are no longer fulfilled, or when a concurrent condition precludes continuation of treatment. Efficacy will be assessed primarily by evaluating progression-free survival (PFS). Participants' safety will be monitored throughout the trial.
Inhalation antifungal formulations based on collapsed microparticles containing carbohydrates and amino acids. Commercial formulations with antifungal agents for the treatment and prophylaxis of lung infections caused by fungi or intracellular pathogens (such as leishmaniasis or tuberculosis) are usually based on lipid excipients and, in most cases, their use is intended for intravenous administration. or by means of aerosols. However, a formulation that allows administration using dry powder inhalers would be more desirable. The present invention describes new pharmaceutical formulations of antifungals in the form of collapsed microparticles that do not contain lipid excipients but rather mono and oligosaccharides, in addition to amino acids so that they can be administered using dry powder inhalers or by aerosols. (Machine-translation by Google Translate, not legally binding)
<P>PROBLEM TO BE SOLVED: To provide granules extremely facilitating the molding, and to provide a method for preparing the granules extremely facilitating the molding.  <P>SOLUTION: The granular composition includes a first powdery composition having the median particle diameter of 10-25 μm, and a second powdery composition having the median particle diameter of 0.1-10 μm. Preferably, at least one of the powdery compositions is composed of calcium carbonate. More preferably, the median particle diameter of the first powdery composition is 12-17 μm, and the median particle diameter of the second powdery composition is 1-5 μm. The granules are useful for tableting a medicament or a functional food, and provide a tablet size smaller than the conventionally available one when being molded.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PROBLEM TO BE SOLVED: To provide a production method of an endoplasmic reticulum dispersion liquid so that endoplasmic reticulum having a two-molecular film multilayered structure including an oil phase show good storage stability and that endoplasmic reticulum having a small particle size can be obtd. SOLUTION: A system comprising a film forming component, oil component and a part of water phase is kneaded at a temp. lower than the phase transition temp. of the film forming component while high shearing force is added so as to produce a liquid crystal compsn. Then the rest of the water phase is added and mixed to the liquid crystal compsn. to form an endoplasmic reticulum dispersion liquid in which the oil component is included in a two- molecular film multilayered structure comprising the film forming component.  By this method for forming the endoplasmic reticulum dispersion liquid, endoplasmic reticulum having the oil component surrounded by the two-molecular film multilayered structure can be stably dispersed in water so that the liquid shows such properties that stability of the oil-inlusion can be improved compared to an O/W emulsion and that the endoplasmic reticulum is not easily broken by other components. By this method, the endoplasmic reticulum dispersion liquid having excellent storage stability can be obtd. without causing separation of the oil component in the dispersion liquid during storage, and especially, the endoplasmic reticulum can be formed to a small size as about 0.1 to 0.5μm average particle size as well as various kinds of oil components can be included.
The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.